GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SAB Biotherapeutics SABS · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.10

+2.31%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Latest on SAB Biotherapeutics

Our reporting

Next results

13 Nov 2026

Due on 13 Nov 2026. Analysts expect earnings of -0.27 a share on revenue of $125,000.

Past results

Reported against what analysts expected

6 Aug 202612 May 20269 Mar 202614 Nov 20257 Aug 202528 Mar 2025
Earnings per share-0.28-0.35-0.46-0.21-1.09-1.23
Forecast-0.28-0.20-0.16-0.59-0.82-1.16
Revenue—————$100,000
Forecast$125,000$125,000$100,000$100,000$83,330$120,000

Key events

  1. 5 Jan 202410-to-1 reverse split
  2. 25 Oct 20211-to-1 reverse split
  3. 12 Jan 2021Listed

SAB Biotherapeutics in the news

Headlines from other publishers, linked to their own pages.

Sources and methodology

Data on this tab
Our reporting and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.